首页 >
法规速递
-
Document: Questions and answers on the outcome of assessment on use of Revolade in treatment of severe aplastic anaemia in children-2025/6/27
2025-06-30查看详情 > -
Page: Ticagrelor product-specific bioequivalence guidance-2025/7/30
2025-07-31查看详情 > -
图解海报 | 《中药生产监督管理专门规定》发布（二）-2025/9/17
2025-09-18查看详情 > -
国家药监局关于发布仿制药参比制剂目录（第九十七批）的通告（2025年第37号）-2025/10/23
2025-10-24查看详情 > -
Document: Product Management Service (PMS) – Frequently Asked Questions (FAQs)-2025/11/25
2025-11-26查看详情 > -
Document: Name Review Group form - questions and answers-2025/12/17
2025-12-18查看详情 > -
Page: Qualification of non-mutagenic impurities - Scientific guideline-2026/2/2
2026-02-03查看详情 > -
Page: Class III implantable devices and Class IIb medical devices intended to administer or remove medicinal products: expert panel opinions-2026/3/10
2026-03-11查看详情 > -
Page: Submitting a maximum residue limit application-2026/4/8
2026-04-09查看详情 > -
国家药监局关于实施《国家中药饮片炮制规范》有关事项的公告（2022年第118号）-2022/12/30
2022-12-30查看详情 >
